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ABSTRACT   
A total of 44 bis-aryl-monocyclic polyamines, monoaryl-monocyclic polyamines and 
their transition metal complexes were prepared, chemically characterized, and screened in vitro 
against the Leishmania donovani promastigotes, axenic amastigotes and intracellular amastigotes 
in THP1 cells.  The IC50 and/or IC90 values showed that 10 compounds were similarly active at 
about 2-fold less potent than known drug pentamidine against promastigotes. The most potent 
compound had an IC50 of 2.82 µM (compared to 2.93 µM for pentamidine). Nine compounds 
were 1.1-13.6-fold more potent than pentamidine against axenic amastigotes, the most potent one 
being about 2-fold less potent than amphotericin B. Fourteen compounds were about 2-10 fold 
more potent than pentamidine, the most potent one is about 2-fold less potent than amphotericin 
B against intracellular amastigotes in THP1 cells. The 2 most promising compounds (FeL7Cl2 
and MnL7Cl2), with strong activity against both promastigotes and amastigotes and no 
observable toxicity against the THP1 cells are the Fe2+- and Mn2+- complexes of a dibenzyl 
cyclen derivative.  Only 2 of the 44 compounds showed observable cytotoxicity against THP1 
cells. Tetraazamacrocyclic monocyclic polyamines represent a new class of antileishmanial lead 
structures that warrant follow up studies. 
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1.  Introduction 
Leishmaniasis, a vector born parasitic disease, affects 350 million people worldwide. 
Visceral leishmaniasis/kala azar (VL) is the most severe form resulting in 20,000 deaths every 
year. The other forms of leishmaniasis are cutaneous leishmaniasis (CL), mucocutaneous 
leishmaniasis (MCL), and post kala azar dermal leishmaniasis (PKDL).1 One to two million new 
cases of the cutaneous form and half a million new cases of the visceral form occur each year. It 
is endemic in 98 countries, closely associated with poverty, with new cases mostly appearing in 
India, Bangladesh, Nepal, Brazil, Kenya, Sudan, and Ethiopia.1,2 Multiple different 
morphological forms arise in the life cycles of Leishmania, differing mainly by the position, 
length and the cell body attachment of the flagellum.3  Amastigotes are a typical morphology 
during an intracellular lifecycle stage in a human host. The promastigote form is a common 
morphology in the insect host. The extracellular form of Leishmania promastigotes is transmitted 
to humans through phlebotomine sandflies. The intracellular form of promastigotes replicates in 
the human host macrophages through a complicated life cycle.3 
The currently available drugs for treatment of leishmaniasis are severely toxic, costly, or 
not effective due to increased resistance. The current first-line drug for treatment of visceral 
leishmaniasis is pentavalent antimonial injections. The injections are inconvenient for therapies, 
lasting up to 21 days, since no oral forms of pentavalent antimonials are currently available. The 
use of pentavalent antimonials as first-line drugs for the past 70 years has led to resistance in 
many areas worldwide.4-6 The second-line drug for therapy is amphotericin B, which requires a 
slow IV infusion and has severe side effects that can potentially be lethal.5,6 Recent clinical trials 
have shown successful treatment of VL with  a single dose of liposomal amphotericin B and 
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combination therapies namely, amphotericB+ miltefosine, amphotericine B+paromomycin, 
miltefosine+ paromomycin and pentavalent antimonials+ paromomycin.7 
  The ability to metabolize polyamines is critical for L. donovani replication and survival. 
The enzymes associated with the pathway of polyamine biosynthesis and transport are promising 
targets for new antileishmanial drug discovery.8-11 The critical enzymes in the metabolic pathway 
are ornithine decarboxylase (ODC), S-adenosylmethionine decarboxylase (AdoMetDC), 
spermidine synthase (SpdS), trypanothione synthetase (TryS), trypanothione reductase (TR)  
tryparedoxin peroxidase (TXNPx), deoxyhypusine synthase (DHS) and deoxyhypusine 
hydroxylase (DOHH).9 Targeting these enzymes can potentially obstruct L. donovani replication. 
The inhibition of growth of L. donovani and L. infantum promastigotes in culture by 
difluoromethyl ornithine (DFMO),12,13 an ODC inhibitor, was the first indication that polyamine 
biosynthesis is a potential drug target for leishmaniasis. Sing et al14 has shown that the 
polyamine depletion due to the inhibition of ODC by 3-aminooxy-1-aminopropane (Fig. 1) is 
leishmanicidal. Leishmania parasites synthesize the polyamines putrescine and spermidine 
through the catalysis by ODC, AdoMetDC, and SpdS. Spermidine is utilized as a substrate to 
synthesize trypanothione for redox control. Trypanothione synthetase (TryS) and trypanothione 
reductase (TR) are two enzymes involved. Ullman and colleagues15-17 have genetically validated 
all these enzymes as drug targets for L. donovani.  
Several polyamine and oligoamine derivatives (Fig. 1) have been reported to have potent 
antileishmanial activity through the interference of polyamine biosynthetic enzymes or transport 
system. 18,19 CGP40215A and MDL73811 are potent inhibitors of AdoMetDC, which have been 
shown to inhibit growth of L. donovani promastigotes at micromolar concentration.16,20 
CGP40215A also inhibits growth of L. donovani amastigotes in mouse macrophages at 
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concentrations up to 90 μM [59].21 The polyamine analogue MDL27695 was shown to eliminate 
77-100% of L. donovani amastigotes from mouse macrophages at a 1 μM concentration, possibly 
by interfering with DNA and RNA synthesis or inhibiting polyamine transport.18,22 The 
oligoamines CGC-11211 and CGC-11226, and the macrocyclic polyamine analogue CGC-11235 
showed potent antileismanial activity in vitro (IC50 < 1μM), predominantly by interfering with 
the polyamine biosynthetic enzymes.19 The polyamine-dependent redox metabolism including 
trypanothione as well as the polyamine transport mechanism have also been shown to be 






















































Figure 1. Representative structures of polyamine and oligoamine derivatives reported to have 
potent antileishmanial activity.18,19 
 
In recent years there has been an increasing interest in the application of polyamines 
analogs and their transition metal complexes in medicine, including against malaria and 
leishmaniasis.27-33 Several reports have shown that incorporation of transition metal ions into 
organic pharmacophores offer molecular diversity in drug discovery in addition to enhancement 
of the biological activity.34-36 The synthetic tetraazamacrocyclic compounds, particularly, cyclen 
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and cyclam, and their analogs or their metal complexes have been extensively utilized in 
applications of a variety of diagnostic and magnetic resonance imaging (MRI) contrast agents.37 
Our group has  extensively investigated  tetraazamacrocycles and their metal complexes in drug 
discovery against variety of disease states including malaria, HIV, cancer, and schistosomiasis.38-
51  The facts that polyamine metabolism and related enzymes are established targets, and several 
oligoamine and polyamine derivatives have shown potent antileishmanial activity, triggered us to 
screen a set of  tetraazamacrocyclic derivatives (Fig. 2) and their metal complexes against L. 
donovani, the causative agent for visceral leishmaniasis as an extension of our antiparasitic drug 
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Figure 2. Structures of the tetraazamacrocyclic ligands used in this study.  
 
2. Results and Discussion 
2.1. Chemistry 
All the ligands L1–L10 in Figure 2 contain only one tetraazamacrocycle and different 
combinations of aromatic units for screening to determine which combination of groups 
maximizes antileishmanial efficacy. Ligands L1 and L2 contain one aromatic group, whereas L3 
– L10 contain two aromatic, or heteroaromatic groups. The tetraazamacrocyclic parent of L1, 
L3-L7 is cyclen, whereas for L2, and L8-L10 it is cyclam. 
 
2.1.1.  Design Principles 
 The tetraazamacrocyclic ligands forming the foundation of this study have all been 
published over the past 20+ years (see experimental section for specific references).  We selected 
a few structural types involving varying substitution patterns, including one, two, or three 
aromatic groups as a way to probe the importance of hydrophobicity to antileishmanial activity.  
We also chose to vary the bridging superstructure included on the macrocycle, from more 
flexible un-bridged, to short and rigid ethylene cross-bridged, to longer and less constrained 
propylene cross-bridged.  The presence of the cross-bridge rigidifies the resulting transition 
metal complex, more fully engulfs the hydrophilic metal ion, and increases the kinetic stability of 
the metal complex compared to unbridged analogues.52  If redox processes involving the metal 
ion of these complexes is involved in the antileishmanial activity, such stabilization would be 
important so that the potential drug molecule does not decompose upon oxidation/reduction. 
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 Finally, we synthesized and screened complexes of the selected ligands with six different 
transition metal ions namely, Mn2+, Fe2+, Co2+, Ni2+, Cu2+ and Zn2+.  The biological significance 
of all of these metal ions are well-known.  They are typically found in a variety of organisms, 
including humans, and are not expected to be toxic, particularly if bound strongly to a 
macrocyclic ligand.  By producing metal complexes, we hoped to change the three-dimensional 
shape, hydrophobicity, and redox reactivity of the resulting potential drug leads.  Choosing a 
range of metal ions allowed us to identify the metal complexes with the most potent 
antileishmanial activity.  Establishing the properties of the most active metal ion complexes 
might help indicate the potential mechanism of action of the lead compounds against leishmania 
For example, Fe/Mn are known to have rich redox chemistries, while Zn is not. 
2.1.2. Synthesis of ligands 
 A representative synthetic scheme for the benzyl substituted cyclam ligands is shown in 
Scheme 1.  All of these ligands are previously published.  Synthesis starting from cyclam 
proceeds through bis-aminals to give regioselective benzylation at non-adjacent nitrogens.  
Removal of the methylene aminal carbons yields L10,53 which can be bridged by ditosyl propane 
to give L9.54  Reductive ring cleavage by sodium borohydride of the dialkylated cyclam-glyoxal 
results in L249 and L8.55  Analogous chemistry starting from cyclen results in L1,51 L3,55 L4,56 
and L7.57   
9 
















































Scheme 1. Synthetic scheme for the literature syntheses of cyclam ligands L2,49 L8,55 L9,54 and 
L10.53  Cyclen analogues L1,51 L3,55 L4,56 and L757 are made by analogous reactions. 
 
The cyclen bisquinoline ligands L5 and L6  were prepared according to the synthetic route 
shown in Scheme 2.39,47 The initial synthesis by direct derivatization using inorganic K2CO3 in 
DMF 39 was inefficient and the desired product (L5) was isolated in low yield (~35%). By choosing 
N-methylpyrrolidinone as the reaction solvent, with triethylamine as base, and elevating the 
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Scheme 2. Synthetic scheme for the literature syntheses of cyclen bisquinoline ligands L5 39,47 
and L6.47  
 


















Scheme 3. Generic complexation reaction illustrated using L2 and showing an acetate complex. 
 Syntheses of Mn2+, Fe2+, Co2+, Ni2+, Cu2+ and Zn2+ complexes were attempted with L1-
L4 and L7-L10 using anhydrous MCl2 and/or M(OAc)2 salts in anhydrous solvents such as 
MeOH, MeCN, and/or DMF (see Scheme 3).  The products of complexations resulting in pure 
complexes are given in Table 1 and specific reaction conditions and basic characterization data 
are given in the Experimental Section.  In general, unbridged tetraazamacrocycles (like L7 and 
L10) can be complexed to metal ions in protic solvents like methanol without the ligand 
preferentially protonating from the solvent.  However, in most cases, complexation to ethylene- 
and propylene-cross-bridged ligands (L1-L4, L8-L9) is most successful in aprotic solvents like 
acetonitrile or dimethylformamide where the highly basic proton sponge ligands are not 
protonated by solvent, which impedes metal ion complexation.52  Complexations were generally 
carried out in an inert atmosphere glovebox to protect the metal ions from air oxidation and the 
ligands from protonation by water.53  Not all complexations were successful, but a significant 
variety of complexes with different metal ion and ligand type were obtained to survey for 
antileishmanial activity among these tetraazamacroyclic ligands and complexes.  Future work 
will include completing the full range of metal complexes for each ligand by finding successful 
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reaction conditions for each metal-ligand pair. The reactions of MnCl2 or FeCl2 with ligand L5 in 
a 1:1 ratio at 80oC for 1 week using DMF as a solvent in a glove box gave the complexes 
Mn(L5)Cl2 and Fe(L5)(Cl2, respectively in 45% and 29% yields, respectively.50  
2.1.4. X-ray Crystallographic Structural Studies 
 In order to better understand the three dimensional structures of these potential drug 
molecules, and to correlate those structures with the biological activity observed, we have 
obtained a number of X-ray crystal structures.  Not all ligands or metal complexes gave X-ray 
quality crystals, but we have obtained crystal structures of the following ligands, either alone or 
in a metal complex: L1, L3, L7, L8, and L10.  We have also previously published additional X-
ray crystal structures of metal complexes of L2,49 L3,58 and L848,51 which will be discussed.  
Tables containing data collection and refinement and metrical parameters for each structure are 
found in the electronic supplementary information. 
  [Cu(L1)Cl]PF6 was prepared and crystallized (Fig. 3) as the acetate complex did not 
crystallize.  In [Cu(L1)Cl]PF6, the copper(II) center adopts a distorted square based pyramidal 
geometry. (Fig. 3a). The tetraazamacrocycle is forced into a folded (cis) arrangement by the 
ethyl bridge, and the ring nitrogens occupy three of the equatorial sites and the axial site, the 
typical coordination geometry for Cu2+ complexes of cross-bridged tetraazamacrocycles.59,60,49,51-
52  The single benzyl group is folded into the open coordination site of the five-coordinate Cu2+, 
which is likely due to packing forces in the solid state, since no close interaction of the benzyl 
group with the metal ion is observed.60  The previously published49 structure of [Cu(L2)(OAc)]+ 
(Fig. 3b) has an acetate bound to the Cu2+ center, and this bulky group causes the benzyl arm to 
be rotated away from the metal ion.  This demonstrated flexibility may play a role in the 
antileishmanial activity discussed below. 
12 




Figure 3. The X-ray crystal structures of a) [Cu(L1)Cl]+ (top) and [Cu(L2)(OAc)]+49 
demonstrate the flexibility of the benzyl group, which can fold toward an empty coordination site 
as in [Cu(L1)Cl]+ or away from a more sterically crowded metal ion as in [Cu(L2)(OAc)]+. 
 
 [Mn(L3)Cl2] (Fig. 4a) has previously been published,58 but none of the other L3 
complexes screened here crystallized.  However, the acetate precursor to [Fe(L3)(OAc)]PF6, 
[Fe(L3)(OAc)2], did form X-ray quality crystals (Fig. 4b).   
13 




Figure 4. The X-ray crystal structures of a) [Mn(L3)Cl2] (left)58 and b) [Fe(L3)(OAc)2] (right). 
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 Both structures have six-coordinate distorted octahedral coordination geometries around 
M2+ ions with folded, or cis, configurations of L3 bonded by all four nitrogen atoms.  
[Mn(L3)Cl2] has both benzyl groups rotated away from the Mn2+ ion and nearly coplanar (24.36o 
of their planes).  However, in [Fe(L3)(OAc)2], the benzyl group to rotate approximately 
perpendicular to the planes of the acetate carboxyl groups in order to fit between them in the 
solid state (65.26o of their planes).  It remains to be determined if this flexibility plays a role in 
antileishmanial activity, or if the simple presence of two hydrophobic benzyl groups, regardless 
of flexibility, is all that is required for increased activity (vide infra). 
 No crystal structures for L4-L6 or L9 are known, according to the Cambridge Database 
(version 5.37) or grown by us.  We include Cu(CB3-DO2A)+ in figure (Fig. 5) 61 to demonstrate 
the similarity to ethylene cross-bridged complexes (L1, L3 above) except for the 3-carbon cross-
bridge, which makes the ligand cavity slightly larger and better able to encapsulate the metal ion 
(Cu2+ in this case).  Obviously L4’s benzyl groups will not be coordinating, and we have 
demonstrated above how they would likely be arranged in complexes of L4.  As dibenzyl 
compounds, some of the L4 compounds demonstrate similar antileishmanial properties as the L3 
compounds (vide infra).  
a)   
15 
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Figure 5. a) The X-ray crystal structure61 of Cu(CB3-DO2A)+ and b) the CB3-DO2A ligand 
 Neutral ligand L8 itself, rather than a metal complex, crystallized from organic solvent.  
In aqueous solution, cross-bridged cyclams are proton sponges and are typically diprotonated.62    
In L8, the cross-bridge extends in front of the page (Fig. 6), showing the cavity for metal 
binding.  Similarly to the [Fe(L3)(OAc)2] complex, the benzyl rings are significantly non-planar 
(plane-plane angle of 54.00o). As will be discussed below, certain metal complexes of these 
ligands are typically more active against Leishmania than the free ligands themselves. 
 
Figure 6. The X-ray crystal structure of L8. 
 The final two X-ray crystal structures to be discussed are Ni(L7)(OAc)+, which 
crystallized when the screened complex Ni(L7)Cl2 did not, and Cu(L10)(DMF)22+, which 
crystallized when the screened complex [Cu(L10)(OAc)]PF6 did not (see Fig. 7).   
16 
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a)   
b)     
Figure 7.  The X-ray crystal structures of a) Ni(L7)(OAc)+ (left) and b) Cu(L10)(DMF)22+. 
 These two crystal structure include, unlike any of those above, unbridged 
tetraazamacrocycles, and demonstrate the configurational flexibility of these ligands by 
producing both a folded (or cis) geometry (Ni(L7)(OAc)+ (Fig. 7a) and a flat (or trans) geometry 
(Cu(L10)(DMF)22+ (Fig. 7b)).  A design principle (vide supra) used in producing this overall set 
of compounds for antileishmanial screening was to determine if the rigid, cross-bridged ligand 
17 
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complexes would be more or less active than the more flexible unbridged analogues.  However, 
these two crystal structures clearly demonstrate the flexibility of the unbridged ligands.  Not only 
are both cis and trans structures achieved, but the benzyl groups show even more rotational 
flexibility than seen in the cross-bridged structures discussed above.  The plane-plane angle in 
Ni(L7)(OAc)+ is 80.41o, the closest to perpendicular we have yet seen.  While this plane-plane 
angle in Cu(L10)(DMF)22+ is 0.00o, making them coplanar (this is also a required outcome of the 
crystallographic space group, P 21/n, where one half of the molecule is the asymmetric unit and 
generates the other.  Both ligand L7 and L10 complexes are, in general, more active against 
leishmania than the cross-bridged ligands presented above.  In fact, the Mn2+ and Fe2+ complexes 
of L7 are identified as the most likely potential drug molecules identified in this study.  Perhaps 
this is a result of the greater flexibility discussed above—a possibility that warrants further 
investigation. 
2.2. Biological Evaluations of In vitro antileishmanial activity  
2.2.1. Antileishmanial activity against promastigotes 
Ten compounds resulting from L1-10 were significantly active to about 2-fold less potent 
than pentamidine against promastigotes. The IC50 values ranged from 2.82 to >20 µM compared 
to 2.93 µM for pentamidine (Table 1). The diaryl-monocyclic polyamine derivatives were more 
active than the monoaryl-monocyclic derivatives. For example, all of the monoaryl compounds’ 
IC50’s were >20 µM and were not further tested, while most of the diaryl compounds and/or their 
metal complexes showed IC50 values less than 20 µM. The most potent is a Mn2+-complex of 
bisbenzyl cyclen derivative (MnL7Cl2), which has an IC50 of 2.82 µM compared to 2.93 µM for 
pentamidine (Table 1). An Fe2+-complex of cyclen bisquinoline (FeL5Cl2) was found to be most 
potent by IC90 values, with IC90 of 7.07 µM compared to 6.52 µM for pentamidine. However, 
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this analog also showed IC50 and IC90 values of 3.95 and 8.79 µM, respectively against THP1 
cells suggesting potential cytotoxicity. No simple conclusion regarding which metal ion (Mn2+, 
Fe2+, Co2+, Ni2+, Zn2+ and Cu2+) best enhanced the antileishmanial activity over the parent 
ligands. However, it was generally observed that Mn2+, Fe2+, and Zn2+-complexes were more 
potent than the corresponding free ligands, with Mn2+-complexes typically being the most potent.  
The three most potent ligands are L3, L9 and L10 with IC50 values 12.68, 12.98 and 9.40 
µM; and IC90 values of 11.44, 18.97, and 17.84 µM, respectively (Table 1). Ligands L3 is a 
dibenzyl ethyl cross-bridged cyclen, L9 and L10 are dibenzyl derivatives of cyclam (Fig. 2).  
The three most potent compounds against promastigotes are Mn(L7)Cl2, Mn(L9)MnCl4 and 
Fe(L5)Cl2, among which only Mn(L7)Cl2 has no toxicity against the THP1 cells, suggesting 
Mn(L7)Cl2 as a lead for further study.  
 
Table 1 
The in vitro Inhibitory Activity of the Monocyclic Compounds against L. donovani. 

























Pentamidine 2.93 6.52 20.42 >25 29.38 9.14 >20 >25 
Amphotericine B 0.134 0.262 0.790 0.959 0.48 1.94 >10 >10 
Bn1Me1Bcyclen (L1) >20 >20 >20 >20 >20 >20 >20 >20 
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[Cu(L1)(OAc)]PF6 >20 >20 >20 >20 >20 >20 >20 >20 
[Zn(L1)(OAc)]PF6 >20 >20 >20 >20 >20 >20 >20 >20 
Bn1Me1Bcyclam (L2) >20 >20 >20 >20 >20 >20 >20 >20 
[Ni(L2)(OAc)]PF6 . 0.35NH4PF6 >20 >20 >20 >20 >20 >20 >20 >20 
[Cu(L2)(OAc)]PF6 >20 >20 >20 >20 >20 >20 >20 >20 
[Zn(L2)OAc)]PF6 >20 >20 >20 >20 >20 >20 >20 >20 
Bn2Bcyclen (L3) 12.68 11.44 15.14 22.29 >25 >25 >25 >25 
Mn(L3)Cl2 18.93 >20 11.50 17.09 >20 >20 >20 >20 
[Fe(L3)(OAc)]PF6 >20 >20 >20 >20 >20 >20 >20 >20 
[Ni(L3)(OAc)]PF6 10.95 >20 >20 >20 >20 >20 >20 >20 
[Cu(L3)(OAc)]PF6 >20 >20 >20 >20 >20 >20 >20 >20 
[Zn(L3)(OAc)]PF6 4.73 >20 13.64 >20 >20 >20 >20 >20 
Bn2PBCyclen (L4) 15.61 >20 >25 >25 18.24 >25 >25 >25 
[Mn(L4)(C2H3O2)]PF6 . 1.9NH4PF6 >10 >10 >10 >10 >10 >10 >10 >10 
[Fe(L4)(C2H3O2)]PF6 . 1.2NH4PF6 >20 >20 >10 >10 >10 >10 >10 >10 
[Co(L4)(C2H3O2)]PF6 . DMF 20.66 >20 >10 >10 >10 >10 >10 >10 
[Zn(L4)(C2H3O2)]PF6 . 0.2DMF 22.92 >20 >10 >10 >10 >10 >10 >10 
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CNBQ (L5) >20 >20 >20 >20 >20 >20 >20 >20 
Mn(L5)Cl2 7.40 11.46 >15 >15 8.59 10.99 13.20 >15 
Fe(L5)Cl2 4.13 7.07 >10 >10 3.52 5.24 3.95 8.79 
Bis-BQ-Cyclen (L6) >20 >20 >20 >20 >20 >20 >20 >20 
Bn2Cyclen (L7) 10.47 >20 >25 >25 - 2.8 >25 >25 
Mn(L7)Cl2 2.82 9.12 >20 >20 1.02 2.40 >20 >20 
Fe(L7)Cl2 5.50 13.09 >15 >15 1.89 6.56 >15 >15 
Ni(L7)Cl2 . 3H2O 18.63 >20 >20 >20 >20 >20 >20 >20 
Bn2Bcyclam (L8) 20.81 >20 >20 >20 10.06 10.43 >20 >20 
Mn(L8)Cl2 21.99 >20 >15 >15 >15 >15 14.27 >15 
Fe(L8)Cl2 7.80 20.09 >15 >15 >15 >15 >15 >15 
[Co(L8)(OAc)]PF6 . H2O 35.29 >20 >15 >15 >15 >15 >15 >15 
[Ni(L8)(OAc)]PF6 6.51 >20 >15 >15 >15 >15 >15 >15 
[Zn(L8)(OAc)]PF6 4.73 >20 >15 >15 >15 >15 >15 >15 
Bn2PBCyclam (L9) 12.98 18.97 18.54 23.11 11.10 11.43 20.63 22.80 
[Mn(L9)][MnCl4] . CH3CN 3.48 9.11 1.50 2.68 1.89 2.17 3.49 5.90 
[Fe(L9)][FeCl4] . H2O 11.69 >20 10.14 >14 11.93 >14 >14 >14 
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[Co(L9)(OAc)1.1](PF6)0.9 . DMF 7.98 >13 10.45 13.09 >13 >13 >13 >13 
[Ni(L9)(OAc)1.1](PF6)0.9 . DMF 9.33 >13 10.12 12.96 >13 >13 >13 >13 
[Zn(L9)(OAc)]PF6.0.3NH4PF6  8.17 10.50 9.91 13.48 7.81 8.53 >14 >14 
Bn2Cyclam (L10) 9.40 17.84 >25 >25 12.93 13.19 >25 >25 
Mn(L10)Cl2 . H2O 6.62 12.36 >19 >19 12.36 12.68 >19 >19 
Fe(L10)Cl2 . 0.5 H2O 5.64 13.91 >19 >15 9.61 9.68 >19 >19 
[Co(L10)(OAc)](PF6) . H2O >15 >15 >15 >15 >15 >15 >15 >15 
Cu(L10)(OAc)](PF6) . H2O >20 >20 >15 >15 >15 >15 >15 >15 
[Zn(L10)(OAc)]PF6 . 0.1H2O 5.65 11.28 >15 >15 6.80 7.04 >15 >15 
 
 
2.2.2. Antileishmanial activity against axenic amastigotes 
L. donovani promastigotes in culture have been transformed into potential amastigotes 
forms, which normally grow intracellularly in the host macrophages. These culture-adapted 
forms are referred as axenic amastigotes and have been suggested as a useful model for in vitro 
antileishmanial screening and also for investigating mechanisms regulating the differentiation, 
survival and pathogenicity of the leishmania parasite.63,64  Against axenic amastigotes, 9 
compounds were 1.1-13.6-fold more potent than pentamidine, the most potent (MnL9MnCl4) 
being about 2-fold less potent than amphotericin B. This compound is also highly potent against 
promastigotes as well as intracellular amastigotes in THP1 cells. However, it is cytotoxic to the 
THP1 cells as mentioned above. Other compounds with reasonable activity against the axenic 
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amastigotes are L9 and all of its metal complexes, among which L9 is the only other compound 
with comparable IC50 and IC90 values against THP1 cells as MnL9MnCl4, again suggesting 
potential toxicity. Against intracellular amastigotes in THP1 cells, 14 compounds were about 2 
to 10-fold more potent than pentamidine, the most potent (MnL7Cl2) is about 2-fold less potent 
than amphotericin B. This same compound was also found to be the most potent against 
promastigotes without sign of toxicity. The second most potent compound against the 
intracellular amastigotes in THP1 cells is Fe(L7)Cl2, without sign of toxicity against the THP1 
cells. This compound was also found to have good activity against promastigotes suggesting 
another potential lead for further study. 
 
2.2.3. Summary of Biological Activity 
In general, the diaryl compounds and their metal complexes (specifically Zn2+, Fe2+, or 
Mn2+ complexes) were found to be more potent compared to the monoaryl system possibly due 
to the higher lipophilicity and thus cell penetration. Two compounds with strong activity against 
both promastigotes and amastigotes and no observable toxicity against the THP1 cells are the 
Fe2+- and Mn2+- complexes of L7, a dibenzyl cyclen derivative (Fig. 2 and Table 1), which 
warrant further investigation.   
The present study revealed several important findings. First, the diaryl monocyclic 
systems are more potent than monoaryl derivatives, perhaps due to more lipophilicity as well. 
Second, Fe2+, and Mn2+ complexes increase the activity of both nonpolar and polar macrocyclic 
derivatives against both promastigotes and amastigotes of leishmanial parasites, although other 
metals also have inconsistently shown improvement in activity. Third, the polyamine ring 
23 
© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
systems are likely to be key structural targets for antileishmanial activity, as all the compounds 
showed reasonable growth inhibition of the leishmania parasites. 
 
3. Conclusions 
The results indicate that excellent antileishmanial potency can be obtained by transition 
metal complexation to tetraazamacrocycles. Interestingly, all of the most active compounds were 
transition metal complexes, not traditional “organic” compounds.  The analogs with hydrophobic 
aryl rings showed higher antileishmanial potency, possibly due to improved cell permeability of 
these analogs. The improvement in the inhibitory potency beyond that of pentamidine required the 
complexation of Fe2+, or Mn2+ and may indicate the role of polyamine biosynthesis and/or oxygen 
radicals formed by the redox cycling of ionic iron and manganese. It has previously been shown 
that several polyamines and oligoamines are potent growth inhibitors of leishmanial parasites 
through inhibition of ODC, AdoMetDC, or polyamine transport system.15,16 This study suggests 
the possible involvement of these compounds with interference of any of these enzymes in the 
polyamine biosynthetic pathway of leishmania parasites. Future detailed mechanistic and stability 
studies involving these ligands, and their metal complexes will be designed to unveil the role of 
complexed metal ions, especially iron, and manganese in antileishmanial activity. This study has 
laid a solid foundation towards the development of a new antileishmanial chemotherapy based on 
tetraazamacrocyclic derivatives and their metal complexes. 
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All the materials were reagent grade, and used as supplied. The reactions were performed in 
anhydrous solvents under inert atmosphere unless otherwise indicated. Anhydrous solvents 
(acetonitrile and DMF) as well as all other reagents were used as received from a commercial 
source. Elemental analysis was carried out by Quantitative Technologies, Inc. in Whitehouse, 
NJ. Electrospray MS was obtained using a Shimadzu LCMS-2020 in 1:1 methanol/ water 
mixture. 1H and 13C NMR spectra were recorded at 300 MHz and 75 MHz, respectively on 
Bruker 300 spectrometer with TMS as internal standard. 
 
4.1.2. Synthesis of ligands and their Metal Complexes 
Several ligands and their metal complexes were synthesized according to literature 
procedures: L1, [Cu(L1)(OAc)]PF6, [Zn(L3)(OAc)]PF6, [Zn(L8)(OAc)]PF6, [Zn(L2)(OAc)]PF6, 
[Cu(L3)(OAc)]PF6, and [Zn(L1)(OAc)]PF6;51 L2 and [Cu(L2)(OAc)]PF6;49 L3, L8,55 and L4;56 
L539,47 Fe(L5)Cl2 and Mn(L5)Cl2;50 L6 39,47, L9;54 L10;53 L7 and;57  [Fe(L3)Cl2], [Mn(L3)Cl2], 
[Mn(L8)Cl2], and [Fe(L8)Cl2]48; [Ni(8)(OAc)]PF6.48  Others were synthesized according to the 
following methods. 
[Ni(L2)(OAc)]PF6 • 0.35NH4PF6: (1.00 mmol, 0.331 g) of L2 and 0.177 g (1.00 mmol) 
of anhydrous nickel(II) acetate were added to 25 ml of dry DMF in an inert atmosphere 
glovebox.  The reaction was stirred at room temperature for 18 h.  The crude 
[Ni(L2)(OAc)][(OAc)] solution was removed from the glovebox, filtered to remove any trace 
solids, and evaporated to dryness.  The crude product was dissolved in 10 ml of dry methanol, to 
which was added dropwise a 5 ml dry methanol solution of 5 equivalents (0.815 g, 5.00 mmol) 
of NH4PF6.  A pale purple powder precipitated, was collected, washed with cold methanol and 
ether, and dried under vacuum. Yield: 0.356 g (60%).  Elemental analysis(%) 
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calcd.  [Ni(C20H34N4)(C2H3O2)]PF6 • 0.35NH4PF6 (650.266 g/mol): C 40.64, H 5.95, N 9.37; 
Found C 40.46, H 5.70, N 9.59.  MS (ES) m/z 447 [Ni(L2)(OAc)]+. 
[Ni(L3)(OAc)]PF6: (1.00 mmol, 0.379 g) of L3 and 0.177 g (1.00 mmol) of anhydrous 
nickel(II) acetate were added to 25 ml of dry DMF in an inert atmosphere glovebox.  The 
reaction was stirred at room temperature for 18 h.  The crude [Ni(L3)(OAc)][(OAc)] solution 
was removed from the glovebox, filtered to remove any trace solids, and evaporated to dryness.  
The crude product was dissolved in 10 ml of dry methanol, to which was added dropwise a 5 ml 
dry methanol solution of 5 equivalents (0.815 g, 5.00 mmols) of NH4PF6.  A pale purple powder 
precipitated, was collected, washed with cold methanol and ether, and dried under vacuum. 
Yield: 0.414 g (67%).  Elemental analysis (%) calcd.  [Ni(C24H34N4)(C2H3O2)]PF6 (641.260 
g/mol): C 48.70, H 5.82, N 8.74; Found C 48.58, H 6.00, N 8.79.  MS (ES) m/z 495 
[NiL(OAc)]+. 
[Mn(L4)(OAc)]PF6 • 1.9NH4PF6: (1.00 mmol, 0.392 g) of L4 and 0.173 g (1.00 mmol) 
of anhydrous manganese(II) acetate were added to 10 ml of dry DMF in an inert atmosphere 
glovebox.  The reaction was stirred at room temperature for 7 days, during which a white powder 
precipitated.  This powder was filtered from solution and washed with minimal DMF and then 
diethyl ether before drying overnight open to the glovebox atmosphere.  The white solid was 
then dissolved in 5 ml MeOH in the glovebox, and 5 equivalents (5.00 mmol, 0.815 g) of 
NH4PF6 dissolved in 3 ml MeOH was added, resulting in precipitation of the white powder 
product (0.194 g, 20%), which was filtered from solution and dried open to the glovebox 
atmosphere.  Elemental analysis(%) calcd.  [Mn(C25H36N4)(C2H3O2)]PF6 • 1.9NH4PF6 (961.230 
g/mol): C 33.74, H 4.89, N 8.60; Found C 33.58, H 5.03, N 8.39.  MS (ES) m/z 445 [Mn(L4)]+. 
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[Fe(L4)(OAc)]PF6 • 1.2NH4PF6: (1.00 mmol, 0.392 g) of L4 and 0.174 g (1.00 mmol) of 
anhydrous iron(II) acetate were added to 10 ml of dry DMF in an inert atmosphere glovebox.  
The reaction was stirred at room temperature for 7 days, during which a light brown powder 
precipitated.  This powder was filtered from solution and washed with minimal DMF and then 
diethyl ether before drying overnight open to the glovebox atmosphere.  The light brown solid 
was then dissolved in 5 ml MeOH in the glovebox, and 5 equivalents (5.00 mmol, 0.815 g) of 
NH4PF6 dissolved in 3 ml MeOH was added, resulting in precipitation of the light brown product 
(0.264 g, 31%), which was filtered from solution and dried open to the glovebox atmosphere.  
Elemental analysis(%) calcd.  [Fe(C25H36N4)(C2H3O2)]PF6 • 1.2NH4PF6 (848.040 g/mol): C 
38.24, H 5.21, N 8.59; Found C 38.32, H 5.14, N 8.59.  MS (ES) m/z 446 [Fe(L4)]+. 
[Co(L4)(OAc)]PF6 • DMF: (1.00 mmol, 0.392 g) of L4 and 0.177 g (1.00 mmol) of 
anhydrous cobalt(II) acetate were added to 10 ml of dry DMF in an inert atmosphere glovebox.  
The reaction was stirred at room temperature for 7 days, during which the solution became deep 
blue.  The solution was removed from the glovebox, filtered to remove trace solids which were 
discarded, and the DMF was removed under vacuum.  The deep purple oily solid remaining was 
then dissolved in 5 ml MeOH to give a pink solution, and 5 equivalents (5.00 mmol, 0.815 g) of 
NH4PF6 dissolved in 3 ml MeOH was added.  This resulted in precipitation of the pink product 
(0.324 g, 44%), which was filtered from solution, washed with methanol and diethyl ether, and 
dried under vacuum.  Elemental analysis(%) calcd.  [Co(C25H36N4)(C2H3O2)]PF6 • DMF (728.62 
g/mol): C 49.45, H 6.36, N 9.61; Found C 49.77, H 6.12, N 9.25.  MS (ES) m/z 452 [Co(L4)]+. 
[Zn(L4)(OAc)]PF6 • 0.2DMF • 0.2H2O: (1.00 mmol, 0.392 g) of L4 and 0.183 g (1.00 
mmol) of anhydrous zinc(II) acetate were added to 10 ml of dry DMF in an inert atmosphere 
glovebox.  The reaction was stirred at room temperature for 7 days, during which the solution 
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became orange.  The solution was removed from the glovebox, filtered to remove trace solids 
which were discarded, and the DMF was removed under vacuum.  The deep yellow solid 
remaining was then dissolved in 5 ml MeOH to give a yellow solution, and 5 equivalents (5.00 
mmol, 0.815 g) of NH4PF6 dissolved in 3 ml MeOH was added.  This resulted in precipitation of 
the tan product (0.337 g, 49%), which was filtered from solution, washed with methanol and 
diethyl ether, and dried under vacuum.  Elemental analysis (%) 
calcd.  [Zn(C25H36N4)(C2H3O2)]PF6 • 0.2DMF • 0.2H2O (683.82 g/mol): C 48.48, H 6.07, N 
8.60; Found C 48.08, H 5.78, N 8.95.  MS (ES) m/z 480 [Zn(L4)Na]+. 
[Mn(L7)Cl2]: (1.00 mmol, 0.353 g) of L7 and 0.126 g (1.00 mmol) of anhydrous 
manganese(II) chloride were added to 10 ml of dry DMF in an inert atmosphere glovebox.  The 
reaction was stirred at room temperature for 7 days, during which a white powder formed.  This 
solid was filtered off inside the glovebox, rinsed with diethyl ether, and allowed to dry open to 
the glovebox atmosphere to give the white powder product.  Yield: 0.211 g (44%).  Elemental 
analysis (%) calcd.  [Mn(C22H32N4)Cl2] (478.36 g/mol): C 55.24, H 6.74, N 11.71; Found C 
55.10, H 6.51, N 11.58.  MS (ES) m/z 455 [Mn(L7)(MeOH)(OH)]+. 
[Fe(L7)Cl2] • 0.4DMF • 0.5 Et2O: (1.00 mmol, 0.353 g) of L7 and 0.127 g (1.00 mmol) 
of anhydrous iron(II) chloride were added to 10 ml of dry DMF in an inert atmosphere glovebox.  
The reaction was stirred at room temperature for 7 days, during which a tan powder formed.  
This solid was filtered off inside the glovebox, rinsed with diethyl ether, and allowed to dry open 
to the glovebox atmosphere to give the white powder product.  Yield: 0.228 g (42%).  Elemental 
analysis (%) calcd.  [Fe(C22H32N4)Cl2] • 0.4DMF • 0.5 Et2O (545.57 g/mol): C 55.48, H 7.35, N 
11.30; Found C 55.96, H 7.23, N 11.76.  MS (ES) m/z 437 [Fe(L7)(MeOH)]+; m/z 481 
[Fe(L7)Cl2]+. 
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[Ni(L7)Cl2] • 3H2O: (1.50 mmol, 0.529 g) of L7 and 0.194 g (1.00 mmol) of anhydrous 
nickel(II) chloride were added to 15 ml of MeOH and 5 ml DMF.  The reaction was heated to 
reflux with stirring under nitrogen for 3 days, during which a clear emerald green solution 
formed.  The solution was cooled to room temperature, filtered to remove trace solids which 
were discarded, and evaporated to dryness forming a green oil.  The oil was dissolved in 10 ml 
MeOH, to which 100 ml diethyl ether was added to precipitate out a green powder product.  The 
green powder product was filtered, washed with diethyl ether, and dried under vacuum.  Yield: 
0.353 g (44%).  Elemental analysis (%) calcd.  [Ni(C22H32N4)Cl2] • 3H2O (482.12 g/mol): C 
49.28, H 7.14, N 10.45; Found C 49.23, H 7.08, N 10.30.  MS (ES) m/z 447 [Ni(L7)Cl]+. 
[Co(L8)(OAc)]PF6 • H2O: (1.00 mmol, 0.407 g) of L8 and 0.177 g (1.00 mmol) of 
anhydrous cobalt(II) acetate were added to 25 ml of dry DMF in an inert atmosphere glovebox.  
The reaction was stirred at room temperature for 18 h.  The crude [Co(L7)(OAc)][(OAc)] 
solution was removed from the glovebox, filtered to remove any trace solids, and evaporated to 
dryness.  The crude products was dissolved in 10 ml of dry methanol, to which was added 
dropwise a 5 ml dry methanol solution of 5 equivalents (0.815 g, 5.00 mmols) of NH4PF6.  A 
pale pink powder precipitated, was collected, washed with cold methanol and ether, and dried 
under vacuum. Yield: 0.416 g (60%).  Elemental analysis (%) 
calcd. [Co(C26H38N4)(C2H3O2)]PF6 • H2O (687.572 g/mol): C 48.91, H 6.30, N 8.15; Found C 
49.19, H 6.50, N 8.29.  MS (ES) m/z 524 [Co(L8)(OAc)]+. 
[Mn(L9)][MnCl4] • CH3CN: (0.452 mmol, 0.190 g) of L9 and 0.063 g (0.500 mmol) of 
anhydrous manganese(II) chloride were added to 5 ml of dry MeCN in an inert atmosphere 
glovebox.  The reaction was stirred at room temperature for 7 days, during which a pale tan 
solution formed.  This solution was filtered to remove trace solids, and evaporated to dryness 
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under vacuum to give the pale tan powder product.  Yield: 0.152 g (85% based on MnCl2).  
Elemental analysis (%) calcd.  [Mn(C27H40N4)][MnCl4] • CH3CN (713.37 g/mol): C 48.83, H 
6.08, N 9.82; Found C 49.65, H 6.47, N 9.47.  MS (ES) m/z 511 [Mn(L9)]+. 
[Fe(L9)][FeCl4] • H2O: (0.452 mmol, 0.190 g) of L9 and 0.064 g (0.500 mmol) of 
anhydrous iron(II) chloride were added to 5 ml of dry MeCN in an inert atmosphere glovebox.  
The reaction was stirred at room temperature for 7 days, during which a brown solution formed.  
This solution was filtered to remove trace solids, and evaporated to dryness under vacuum to 
give the brown powder product.  Yield: 0.137 g (79% based on FeCl2).  Elemental analysis (%) 
calcd.  [Fe(C27H40N4)][FeCl4] • H2O (692.15 g/mol): C 46.85, H 6.11, N 8.10; Found C 46.97, H 
5.71, N 7.85.  MS (ES) m/z 512 [Fe(L9)]+. 
[Co(L9)(OAc)1.1](PF6)0.9 • DMF: (0.500 mmol, 0.211 g) of L9 and 0.089 g (0.500 mmol) 
of anhydrous cobalt(II) acetate were added to 10 ml of dry DMF in an inert atmosphere glovebox 
and stirred overnight, forming a bright blue solution.  The solution was removed from the 
glovebox, filtered to remove trace solids which were discarded, and evaporated to dryness 
forming a bright blue oil.  The oil was dissolved in 7 ml dry MeOH, to which a 3 ml MeOH 
solution of 5 equivalents (2.50 mmol, 0.408 g) of NH4PF6 was added with stirring, and then 
stored overnight at -10 oC.  The pink powder product was filtered, washed with methanol and 
diethyl ether, and dried under vacuum.  Yield: 0.183 g (49%).  
[Co(C27H40N4)(C2H3O2)1.1](PF6)0.9 • DMF (748.08 g/mol): C 51.70, H 6.78, N 9.36; Found C 
51.61, H 7.09, N 9.37.  MS (ES) m/z 557 [Co(L9)(OAc)(H2O)]+. 
[Ni(L9)(OAc)1.1](PF6)0.9 • DMF: (0.500 mmol, 0.211 g) of L9 and 0.089 g (0.500 mmol) 
of anhydrous nickel(II) acetate were added to 10 ml of dry DMF in an inert atmosphere glovebox 
and stirred overnight, forming a brown solution.  The solution was removed from the glovebox, 
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filtered to remove trace solids which were discarded, and evaporated to dryness forming a brown 
oil.  The oil was dissolved in 5 ml dry MeOH, to which a 2 ml MeOH solution of 5 equivalents 
(2.50 mmol, 0.408 g) of NH4PF6 was added with stirring, and then stored overnight at -10 oC.  
The green powder product was filtered, washed with methanol and diethyl ether, and dried under 
vacuum.  Yield: 0.154 g (41%).  [Ni(C27H40N4)(C2H3O2)1.1](PF6)0.9 • DMF (747.84 g/mol): C 
51.72, H 6.78, N 9.36; Found C 51.49, H 6.98, N 9.45.  MS (ES) m/z 595 [Ni(L9)(OAc)2]+. 
[Zn(L9)(OAc)]PF6 • 0.3NH4PF6: (0.500 mmol, 0.211 g) of L8 and 0.089 g (0.500 mmol) 
of anhydrous zinc(II) acetate were added to 10 ml of dry DMF in an inert atmosphere glovebox 
and stirred overnight, forming an orange solution.  The solution was removed from the glovebox, 
filtered to remove trace solids which were discarded, and evaporated to dryness forming an 
orange oil.  The oil was dissolved in 2 ml water, to which a 2 ml water solution of 5 equivalents 
(2.50 mmol, 0.408 g) of NH4PF6 was added with stirring, and then stored overnight at 5 oC.  The 
brown sticky solid product was filtered, washed with methanol and diethyl ether, dissolved in 5 
ml MeCN, and finally precipitated with 100 ml diethyl ether to give a brown powder product, 
which was dried under vacuum.  Yield: 0.150 g (41%).  [Zn(C27H40N4)(C2H3O2)](PF6) • 
0.3NH4PF6 (738.95 g/mol): C 47.14, H 6.03, N 8.15; Found C 47.25, H 6.03, N 8.12.  MS (ES) 
m/z 547 [Zn(L9)(OAc)]+. 
[Mn(L10)Cl2] • H2O: (1.00 mmol, 0.381 g) of L10 and 0.126 g (1.00 mmol) of 
anhydrous manganese(II) chloride were added to 15 ml of dry MeOH in an inert atmosphere 
glovebox.  The reaction was stirred at room temperature for 14 days, during which a white 
powder formed.  This solid was filtered off inside the glovebox, and allowed to dry open to the 
glovebox atmosphere to give the white powder product.  Yield: 0.307 g (59%).  Elemental 
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analysis (%) calcd.  [Mn(C24H36N4)Cl2] • H2O (524.43 g/mol): C 54.97, H 7.30, N 10.68; Found 
C 54.98, H 7.05, N 10.43.  MS (ES) m/z 471 [Mn(L10)Cl]+. 
[Fe(L10)Cl2] • 0.5H2O: (1.00 mmol, 0.381 g) of L10 and 0.127 g (1.00 mmol) of 
anhydrous iron(II) chloride were added to 15 ml of dry MeOH in an inert atmosphere glovebox.  
The reaction was stirred at room temperature for 14 days, during which a white powder formed.  
This solid was filtered off inside the glovebox, and allowed to dry open to the glovebox 
atmosphere to give the off-white powder product.  Yield: 0.283 g (55%).  Elemental analysis (%) 
calcd.  [Fe(C24H36N4)Cl2] • 0.5H2O (516.33 g/mol): C 55.83, H 7.22, N 10.85; Found C 55.65, H 
7.11, N 10.45.  MS (ES) m/z 435 [Fe(L19)]+; m/z 470 [Fe(L9)Cl]+. 
[Co(L10)(OAc)](PF6) • H2O: 0.425 g (0.0011 mol) of 1,8-dibenzylcyclam and 0.195 g 
(0.0011 mol) of anhydrous cobalt(II) acetate were added to a 20 ml reaction vial in an inert 
atmosphere glovebox and 15 ml of anhydrous methanol was added. The reaction was stirred at 
room temperature for 7 days. The reaction vial was removed from the glovebox and the workup 
was done in air. The reaction solution was filtered through celite in a Pasteur pipette into a 100 
mL roundbottom flask to remove any trace solids which were discarded. Separately, 5 
equivalents (0.0055 mol, 0.897 g) of NH4PF6 was dissolved in a minimal amount of methanol 
(~5 ml) and added with stirring to the metal complex solution. A precipitate of the pink complex 
as a PF6- salt formed immediately. The reaction flask was placed in a freezer (-10 oC) for 1 hour 
to complete the precipitation of the product. The solid pink powder product was collected on a 
fine glass frit, washed with a minimal amount of cold methanol, then ether. The pink powder 
product was transferred to a 4-dram vial and dried overnight under vacuum. Yield = 0.506 g 
(70%).  [Co(C24H36N4)(C2H3O2)](PF6) • H2O (661.53 g/mol): C 47.21, H 6.25, N 8.47; Found C 
47.45, H 6.07, N 8.53.  MS (ES) m/z 470 [Co(L10)(OAc)]+. 
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[Cu(L10)](PF6)2 • H2O: 0.425 g (0.0011 mol) of 1,8-dibenzylcyclam and 0.199 g (0.0011 
mol) of anhydrous copper(II) acetate were added to a 20 ml reaction vial in an inert atmosphere 
glovebox and 15 ml of anhydrous methanol was added. The reaction was stirred at room 
temperature for 7 days. The reaction vial was removed from the glovebox and the workup was 
done in air. The reaction solution was filtered through celite in a Pasteur pipette into a 100 mL 
roundbottom flask to remove any trace solids which were discarded. Separately, 5 equivalents 
(0.0055 mol, 0.897 g) of NH4PF6 was dissolved in a minimal amount of methanol (~5 ml) and 
added with stirring to the metal complex solution. A precipitate of the bright blue complex as a 
PF6- salt formed immediately. The reaction flask was placed in a freezer (-10 oC) for 1 hour to 
complete the precipitation of the product. The solid bright blue powder product was collected on 
a fine glass frit, washed with a minimal amount of cold methanol, then ether. The bright blue 
powder product was transferred to a 4-dram vial and dried overnight under vacuum. Yield = 
0.291 g (37%).  [Cu(C24H36N4)](PF6)2 • H2O (752.06 g/mol): C 38.33, H 5.09, N 7.45; Found C 
38.69, H 4.74, N 7.38.  MS (ES) m/z 222 [Cu(L10)]2+. 
[Zn(L10)(OAc)]PF6 • 0.1H2O: (1.00 mmol, 0.381 g) of L10 and 0.183 g (1.00 mmol) of 
anhydrous zinc(II) acetate were added to 15 ml of dry MeOH in an inert atmosphere glovebox.  
The reaction was stirred at room temperature for 7 days, during which the solution became 
yellow.  The solution was removed from the glovebox and filtered to remove trace solids, which 
were discarded.  5 equivalents (5.00 mmol, 0.815 g) of NH4PF6 dissolved in 3 ml MeOH was 
added.  This resulted in precipitation of the tan product (0.176 g, 27%), which was filtered from 
solution, washed with methanol and diethyl ether, and dried under vacuum.  Elemental analysis 
(%) calcd.  [Zn(C24H36N4)(C2H3O2)]PF6 • 0.1H2O (651.79 g/mol): C 47.91, H 6.06, N 8.60; 
Found C 48.05, H 6.05, N 8.62.  MS (ES) m/z 503 [Zn(L10)(OAc)]+. 
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4.2. Biological evaluation 
4.2.1. In vitro antileishmanial activity 
The compounds were tested for different cellular forms of L. donovani namely  promastigotes, 
axenic amastigotes and intracellular  amastigotes in differentiated THP1 macrophages. These 
assays have been adapted to 384 well micro-plate format. A 3-4 days’ old culture of L. donovani 
promastigotes or axenic amastigotes in the exponential phase was diluted with RPMI medium to 
1 X 106 cells/ml for antileishmanial assays. The samples with appropriate dilutions were added 
to the promastigotes and axenic amastigotes  cultures.  The compounds were tested at six 
concentrations ranging from 10 to 0.0032 µg/ml. The plates were incubated at 26 °C for 72 hours 
(37 °C for axenic amastigotes) and growth of the parasites in cultures were determined by alamar 
Blue assay as described earlier.65,66 The compounds were also tested against L. donovani 
intracellular amastigotes in THP1 cells employing a recently developed parasite-rescue and 
transformation assay.67 The test samples were tested for cytotoxicity against THP1 cell cultures 
simultaneously. The conditions for seeding the THP1 cells, exposure to the test compounds and 
evaluation of cytotoxicity were the same as described in the parasite-rescue and transformation 
assay. IC50 and IC90 values were computed from the dose response curves usingXLFit®.  
4.3. X-Ray Crystallography 
Single crystal X-ray diffraction data were collected for NiL7 at beamline 11.3.1 at the Advanced 
Light Source (λ = 0.7749 Å), USA using a Bruker D8 diffractometer with PHOTON100 
detector. The crystal was held at 150 K in an Oxford Cryosystems Cryostream Plus. Data were 
processed using Bruker APEX2 and SAINT68 software and corrected for the effects of 
absorption by SADABS.69  Single crystal X-ray diffraction data for all other structures were 
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collected using a Stoe IPDS2 diffractometer with monochromated Mo Kα radiation (λ = 0.71073 
Å). Crystals were held at 150 K in an Oxford Cryosystems Cryostream. Data were processed 
using Stoe X-AREA suit of programs. For FeL3 and CuL10 a multi-scan absorption correction 
was carried out within Sortav.70 Crystal structures were solved using SHELXT (ref 3) and 
refined against all unique F2 values using SHELXL.71  Hydrogen atoms were added at 
geometrically calculated positions except in the case of those attached to nitrogen or oxygen, for 
which atom positions were refined subject to chemically-sensible restraints.  
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Appendix A. Supplementary data 
CCDC 1555221-1555225 contain the supplementary crystallographic data for [Cu(L1)Cl]PF6, 
[Fe(L3)(OAc)2], L8, [Ni(L7)(OAc)]PF6 . (CH3)2CO, and [Cu(L10)(DMF)2](PF6)2  . 2DMF, 
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respectively. These data can be obtained free of charge via 
http://www.ccdc.cam.ac.uk/conts/retrieving.html, or from the Cambridge Crystallographic Data 
Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or e-mail: 
deposit@ccdc.cam.ac.uk. Supplementary data associated with this article can be found, in the 
online version, at http:// 
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